Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study.

Sonja Brajovic,Christine Caligtan,Meaghan Zisk,David A Blaser,Carol A Pamer,Sally Okun,Marni Hall

doi:10.2196/medinform.9878

Abstract

BackgroundThe availability of and interest in patient-generated health data (PGHD) have grown steadily. Patients describe medical experiences differently compared with how clinicians or researchers would describe their observations of those same experiences. Patients may find nonserious, known adverse drug events (ADEs) to be an ongoing concern, which impacts the tolerability and adherence. Clinicians must be vigilant for medically serious, potentially fatal ADEs. Having both perspectives provides patients and clinicians with a complete picture of what to expect from drug therapies. Multiple initiatives seek to incorporate patients’ perspectives into drug development, including PGHD exploration for pharmacovigilance. The Food and Drug Administration (FDA) Adverse Event Reporting System contains case reports of postmarketing ADEs. To facilitate the analysis of these case reports, case details are coded using the Medical Dictionary for Regulatory Activities (MedDRA). PatientsLikeMe is a Web-based network where patients report, track, share, and discuss their health information. PatientsLikeMe captures PGHD through free-text and structured data fields. PatientsLikeMe structured data are coded to multiple medical terminologies, including MedDRA. The standardization of PatientsLikeMe PGHD enables electronic accessibility and enhances patient engagement.ObjectiveThe aim of this study is to retrospectively review PGHD for symptoms and ADEs entered by patients on PatientsLikeMe and coded by PatientsLikeMe to MedDRA terminology for concordance with regulatory-focused coding practices.MethodsAn FDA MedDRA coding expert retrospectively reviewed a data file containing verbatim patient-reported symptoms and ADEs and PatientsLikeMe-assigned MedDRA terms to determine the medical accuracy and appropriateness of the selected MedDRA terms, applying the International Council for Harmonisation MedDRA Term Selection: Points to Consider (MTS:PTC) guides.ResultsThe FDA MedDRA coding expert reviewed 3234 PatientsLikeMe-assigned MedDRA codes and patient-reported verbatim text. The FDA and PatientsLikeMe were concordant at 97.09% (3140/3234) of the PatientsLikeMe-assigned MedDRA codes. The 2.91% (94/3234) discordant subset was analyzed to identify reasons for differences. Coding differences were attributed to several reasons but mostly driven by PatientsLikeMe’s approach of assigning a more general MedDRA term to enable patient-to-patient engagement, while the FDA assigned a more specific medically relevant term.ConclusionsPatientsLikeMe MedDRA coding of PGHD was generally comparable to how the FDA would code similar data, applying the MTS:PTC principles. Discordant coding resulted from several reasons but mostly reflected a difference in purpose. The MTS:PTC coding principles aim to capture the most specific reported information about an ADE, whereas PatientsLikeMe may code patient-reported symptoms and ADEs to more general MedDRA terms to support patient engagement among a larger group of patients. This study demonstrates that most verbatim reports of symptoms and ADEs collected by a PGHD source, such as the PatientsLikeMe platform, could be reliably coded to MedDRA terminology by applying the MTS:PTC guide. Regarding all secondary use of novel data, understanding coding and standardization principles applied to these data types are important.

Highlights

Patients describe their medical experiences differently compared with how clinicians or researchers would describe their observations
Coding differences were attributed to several reasons but mostly driven by PatientsLikeMe’s approach of assigning a more general Medical Dictionary for Regulatory Activities (MedDRA) term to enable patient-to-patient engagement, while the Food and Drug Administration (FDA) assigned a more specific medically relevant term
PatientsLikeMe MedDRA coding of patient-generated health data (PGHD) was generally comparable to how the FDA would code similar data, applying the MedDRA Term Selection: Points to Consider (MTS):MedDRA Term Selection (PTC) principles

Summary

Introduction

Patients describe their medical experiences differently compared with how clinicians or researchers would describe their observations. A patient may find a nonserious, known adverse drug event (ADE) to be an ongoing, daily concern, which impacts tolerability and adherence. Clinicians, must be vigilant for medically serious or potentially fatal ADEs. Clinicians, must be vigilant for medically serious or potentially fatal ADEs Having both perspectives can provide patients and clinicians with a complete picture of what to expect from drug therapy options for a given medical condition. Known adverse drug events (ADEs) to be an ongoing concern, which impacts the tolerability and adherence. Clinicians must be vigilant for medically serious, potentially fatal ADEs. Clinicians must be vigilant for medically serious, potentially fatal ADEs Having both perspectives provides patients and clinicians with a complete picture of what to expect from drug therapies. The standardization of PatientsLikeMe PGHD enables electronic accessibility and enhances patient engagement

Methods

Results

Discussion

Conclusion